PMID-37845598 – Thymosin Alpha-1 in COVID-19: Systematic Review and Meta-Analysis
Soeroto AY et al. "The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression," Inflammopharmacology, 2023;31(6):3317-3325. doi:10.1007/s10787-023-01354-2
Quick Reference
| Property | Value |
|---|---|
| PMID | 37845598 |
| DOI | 10.1007/s10787-023-01354-2 |
| Year | 2023 |
| Journal | Inflammopharmacology |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | 8 studies pooled (COVID-19 patients) |
| Peptide(s) Studied | Thymosin Alpha-1 |
Key Findings
- Thymosin alpha-1 significantly reduced mortality in moderate-to-critical COVID-19 patients vs. controls
- No significant difference in mechanical ventilation needs or hospital length of stay
- Meta-regression identified potential effect modifiers
- Authors note additional RCTs needed to confirm findings
Study Design
Systematic review and meta-analysis of 8 studies evaluating thymosin alpha-1 in hospitalized COVID-19 patients. PRISMA-compliant. Included meta-regression analysis to explore heterogeneity.
Limitations
- Predominantly observational studies in the meta-analysis; limited RCT data
- Most studies from China during early pandemic waves
- COVID-19 treatment landscape has evolved significantly since these studies
Clinical Relevance
Provides Level I evidence synthesis for thymosin alpha-1 in acute viral infection. The mortality benefit signal is clinically significant, though the observational study base limits confidence. Relevant for the Immune Restoration Protocol and the pandemic-era evidence for immunomodulatory peptides.
Related
#research #systematic-review #evidence-level-I